

1 **Title:** Neuropeptide VF neurons promote sleep via the serotonergic raphe

2

3

4 **Authors:** Daniel A. Lee¹, Grigorios Oikonomou¹, Tasha Cammidge¹, Young Hong¹, David A.
5 Prober^{1,*}

6

7 **Affiliations:**

8 ¹California Institute of Technology, Division of Biology and Biological Engineering, Pasadena, CA
9 91125, USA

10

11 * Correspondence: dprober@caltech.edu

12

13 **Keywords:** Sleep, arousal, neuropeptide VF, serotonin, 5-HT, raphe, optogenetics

14

15 **ABSTRACT**

16 Although several sleep-regulating neurons have been identified, little is known about how they
17 interact with each other for sleep/wake control. We previously identified neuropeptide VF (NPVF)
18 and the hypothalamic neurons that produce it as a sleep-promoting system (Lee et al., 2017).
19 Here we use zebrafish to describe a neural circuit in which *neuropeptide VF (npvf)*-expressing
20 neurons control sleep via the serotonergic raphe nuclei (RN), a hindbrain structure that promotes
21 sleep in both diurnal zebrafish and nocturnal mice. Using genetic labeling and calcium imaging,
22 we show that *npvf*-expressing neurons innervate and activate serotonergic RN neurons. We
23 additionally demonstrate that optogenetic stimulation of *npvf*-expressing neurons induces sleep
24 in a manner that requires NPVF and is abolished when the RN are ablated or lack serotonin.
25 Finally, genetic epistasis demonstrates that NPVF acts upstream of serotonin in the RN to
26 maintain normal sleep levels. These findings reveal a novel hypothalamic-hindbrain circuit for
27 sleep/wake control.

28

29 INTRODUCTION

30 While several sleep- and wake-promoting neuronal populations have been identified (reviewed in
31 (Bringmann, 2018; Liu and Dan, 2019; Saper and Fuller, 2017; Scammell et al., 2017)),
32 characterizing and understanding the functional and hierarchical relationships between these
33 populations is essential for understanding how the brain regulates sleep and wake states
34 (Oikonomou and Prober, 2017). Recent evidence from zebrafish and mice demonstrate that the
35 serotonergic raphe nuclei (RN) are critical for the initiation and maintenance of sleep (Oikonomou
36 et al., 2019), in contrast with previous models suggesting a wake-promoting role for the RN that
37 were largely based on their wake-active nature (Saper and Fuller, 2017; Scammell et al., 2017;
38 Weber and Dan, 2016). In zebrafish, mutation of *tryptophan hydroxylase 2 (tph2)*, which is
39 required for serotonin (5-HT) synthesis in the RN, results in reduced sleep, sleep depth, and
40 homeostatic response to sleep deprivation (Oikonomou et al., 2019). Pharmacological inhibition
41 of 5-HT synthesis or ablation of the RN also results in reduced sleep. Consistent with a sleep-
42 promoting role for the raphe, optogenetic stimulation of raphe neurons results in increased sleep.
43 Similarly, in mice, ablation of the RN results in increased wakefulness and an impaired
44 homeostatic response to sleep deprivation, whereas tonic optogenetic stimulation of the RN at a
45 rate similar to their baseline pattern of activity induces NREM sleep. These complementary results
46 in zebrafish and mice (Oikonomou et al., 2019), along with classical ablation and pharmacological
47 studies (Ursin, 2008), indicate an evolutionarily conserved role for the serotonergic system in
48 promoting vertebrate sleep. However, it is unclear how the RN are themselves regulated to
49 promote sleep.

50

51 Trans-synaptic retrograde viral tracing studies have identified substantial inputs to the RN from
52 hypothalamic neurons in the lateral hypothalamic area, tuberomammillary nucleus, and
53 dorsomedial nucleus, regions implicated in sleep-wake regulation (Pollak Dorocic et al., 2014;
54 Ren et al., 2018; Weissbourd et al., 2014). However, it is unknown whether any of these or other

55 populations act upon the RN to promote sleep. One candidate neuronal population expresses the
56 sleep-promoting neuropeptide VF (NPVF) in ~25 neurons in the larval zebrafish hypothalamus
57 (Lee et al., 2017). Overexpression of *npvf* or stimulation of *npvf*-expressing neurons results in
58 increased sleep, whereas pharmacological inhibition of NPVF signaling or ablation of *npvf*-
59 expressing neurons results in reduced sleep (Lee et al., 2017). While it is unknown how the NPVF
60 system promotes sleep, these neurons densely innervate a region of the hindbrain that is
61 consistent with the location of the RN (Lee et al., 2017; Madelaine et al., 2017). Because
62 perturbations of the NPVF system and RN have similar effects on sleep, and processes of *npvf*-
63 expressing neurons are found near the RN, we hypothesized that the NPVF system promotes
64 sleep via the RN. To test this hypothesis, we used genetics, optogenetics, and chemogenetics to
65 dissect the functional relationship between these two neuronal populations. Our results support
66 the hypothesis that the NPVF system promotes sleep via the RN, thus revealing a novel
67 hypothalamus-hindbrain neural circuit for sleep-wake control.

68

69 **RESULTS**

70 **NPVF neurons densely innervate the serotonergic inferior raphe nuclei**

71 In most vertebrates, the RN are the main source of serotonergic innervation in the brain. In
72 mammals, the RN are divided into a rostral or superior group that lies on the midbrain/pons
73 boundary (groups B5–B9) (Dahlstroem and Fuxe, 1964), and a caudal or inferior group in the
74 medulla (groups B1–B3). Similarly, in zebrafish larvae, the RN are divided into the superior raphe
75 (SRa) and inferior raphe (IRa) (Lillesaar et al., 2009).

76

77 To explore whether the NPVF system may promote sleep via the RN, we first performed a detailed
78 histological analysis of these populations using *Tg(npvf:eGFP)* (Lee et al., 2017) and
79 *Tg(npvf:KalTA4); Tg(UAS:nfsb-mCherry)* (Agetsuma et al., 2010; Lee et al., 2017) animals, which
80 specifically label *npvf*-expressing neurons. As previously described (Lee et al., 2017), the soma

81 of *npvf*-expressing neurons are present exclusively in the dorsomedial hypothalamus at 6 days
82 post-fertilization (dpf) (**Figure 1A,B,D**). These neurons send dense and local ramifying projections
83 into the hypothalamus (**Figure 1B,D**), as well as longer-range projections into the telencephalon
84 and hindbrain, with a prominent convergence of these projections at the rostral IRa, as confirmed
85 using 5-HT immunohistochemistry (IHC) (**Figure 1B-1K, Figure 1 - figure supplement 1A-B**).
86 These projections form a dense bundle just ventral to the soma of the IRa and also extend dorsally
87 where they appear to make multiple contacts with IRa somas. As additional confirmation of this
88 interaction, we mated *Tg(npvf:KalTA4); Tg(UAS:nfsb-mCherry)* (Agetsuma et al., 2010; Lee et
89 al., 2017) animals, in which NPVF neurons and their processes are labeled with mCherry, to
90 *Tg tph2:eNTR-mYFP* animals, in which the SRA and IRa are labeled with membrane-targeted
91 YFP (Oikonomou et al., 2019). We observed apparent direct contacts of NPVF neuron fibers with
92 mYFP-labeled IRa soma and fibers (**Figure 1 - figure supplement 1C-E**), consistent with a direct
93 interaction between NPVF and IRa neurons.

94

95 **Optogenetic stimulation of NPVF neurons results in activation of serotonergic IRa neurons**

96 Based on our histological observations, we hypothesized that NPVF neurons are functionally
97 connected to serotonergic IRa neurons, and that stimulation of NPVF neurons should thus
98 activate IRa neurons. To test this hypothesis, we used *Tg(npvf:ReaChR-*
99 *mCitrine);Tg(tph2:GCaMP6s-tdTomato)* animals (Lee et al., 2017; Oikonomou et al., 2019) to
100 optogenetically stimulate NPVF neurons while monitoring the activity of IRa neurons. Because
101 neurons in the RN are responsive to visible light (Cheng et al., 2016), we used invisible 920 nm
102 two-photon light at low laser power to excite GCaMP6s fluorescence. We also used 920 nm two-
103 photon light, applied at higher power, to stimulate ReaChR in NPVF neurons.

104

105 To verify that this stimulation paradigm indeed results in stimulation of NPVF neurons, we first
106 tested *Tg(npvf:ReaChR-mCitrine); Tg(npvf:GCaMP6s-tdTomato)* animals (Lee et al., 2017; Lee

107 et al., 2019). We first recorded baseline GCaMP6s fluorescence in *npvf*-expressing neurons, then
108 optogenetically stimulated these neurons, and then recorded post-stimulation GCaMP6s
109 fluorescence in these neurons (**Figure 2 - figure supplement 1**). In the frame after compared to
110 the frame before optogenetic stimulation, we observed a 165% increase in GCaMP6s
111 fluorescence in NPVF neurons in *Tg(npvf:ReaChR-mCitrine)* animals ($p < 0.0005$, Mann-Whitney
112 test, 5 animals, 86 neurons) (**Figure 2 - figure supplement 1H,I**). In contrast, there was a 3%
113 decrease in GCaMP6s fluorescence in the first frame after compared to the frame before
114 optogenetic stimulation using the same imaging paradigm in *Tg(npvf:eGFP)* control animals
115 ($p < 0.01$, Mann-Whitney test, 5 animals, 95 neurons) (**Figure 2 - figure supplement 1I**). Thus,
116 our stimulation paradigm results in robust ReaChR-dependent activation of *npvf*-expressing
117 neurons.

118
119 We next used the same stimulation and imaging paradigm to ask whether optogenetic stimulation
120 of NPVF neurons results in activation of neurons in the IRa using *Tg(npvf:ReaChR-mCitrine);*
121 *Tg(tph2:GCaMP6s-tdTomato)* animals (Lee et al., 2017; Oikonomou et al., 2019). To do so, we
122 first recorded baseline GCaMP6s fluorescence in *tph2*-expressing IRa neurons, then stimulated
123 *npvf*-expressing neurons as described above, and then recorded post-stimulation GCaMP6s
124 fluorescence in IRa neurons (**Figure 2A,B**). In the frame immediately following optogenetic
125 stimulation, we observed a 40% increase in GCaMP6s fluorescence in IRa neurons ($p < 0.0001$,
126 Mann-Whitney test, 4 animals, 154 neurons) that gradually declined to baseline after ~ 40
127 seconds (**Figure 2C, E,F**). This extended decay of GCaMP6s fluorescence is consistent with the
128 prolonged effect expected for neuropeptide/G-protein coupled receptor (GPCR) signaling (van
129 den Pol, 2012). Notably, while 74% of *tph2*-expressing neurons displayed an increase in
130 GCaMP6s fluorescence immediately following stimulation (average \pm SEM $\Delta F/F = 63 \pm 6\%$, 116 of
131 154 neurons), 26% of IRa neurons showed decreased fluorescence (average \pm SEM $\Delta F/F = -$
132 $27 \pm 4\%$, 38 of 154 neurons), demonstrating a heterogeneity in response profiles among IRa

133 neurons. These effects were due to optogenetic stimulation of NPVF neurons, as they were not
134 observed in *Tg(npvf:eGFP); Tg tph2:GCaMP6s-tdTomato* control animals (**Figure 2C,D,F**).
135 These results demonstrate that stimulation of NPVF neurons results in activation of serotonergic
136 IRa neurons, likely via neuropeptide/GPCR signaling.

137

138 **Loss of *npvf* does not enhance the *tph2* mutant sleep phenotype**

139 The NPVF prepro-peptide is processed to produce three mature neuropeptides, RFRP 1-3
140 (Hinuma et al., 2000). We previously generated zebrafish that contain a frameshift mutation within
141 the *npvf* gene that is predicted to encode a protein that contains RFRP1 but lacks RFRP2 and
142 RFRP3 (Lee et al., 2017). We have shown that loss of NPVF signaling due to this mutation (Lee
143 et al., 2017), or loss of 5-HT production in the RN due to mutation of *tph2* (Oikonomou et al.,
144 2019), results in decreased sleep. Based on our observations that NPVF neurons project to and
145 can stimulate serotonergic IRa neurons (**Figure 1,2**), we next tested the hypothesis that *npvf* and
146 *tph2* act in the same genetic pathway to promote sleep. We tested this hypothesis by comparing
147 the sleep of *npvf*^{-/-}; *tph2*^{-/-} animals to their heterozygous mutant sibling controls (**Figure 3**). We
148 reasoned that if *npvf* and *tph2* promote sleep via independent genetic pathways, then animals
149 lacking both genes should sleep more than either single mutant. In contrast, if *npvf* and *tph2*
150 promote sleep in the same pathway, then loss of both genes should not result in an additive sleep
151 phenotype. Similar to previous results, animals containing a homozygous mutation in either *npvf*
152 or *tph2* slept less than heterozygous mutant sibling controls, with *tph2* mutants showing a stronger
153 phenotype (**Figure 3B,C,E**). However, *npvf*^{-/-}; *tph2*^{-/-} animals did not sleep significantly more
154 than their *npvf*^{+/-}; *tph2*^{-/-} siblings (**Figure 3D,E**). Thus, loss of *npvf* does not enhance the *tph2*
155 mutant phenotype, consistent with the hypothesis that *tph2* acts downstream of *npvf* to promote
156 sleep.

157

158 **Sleep induced by stimulation of *npvf*-expressing neurons requires *npvf***

159 We previously showed that optogenetic stimulation of NPVF neurons is sufficient to promote sleep
160 in zebrafish (Lee et al., 2017). However, it is unknown whether this phenotype is due to release
161 of the NPVF neuropeptide or other factors within these cells, such as the fast neurotransmitter
162 glutamate (Lee et al., 2017). To directly test the hypothesis that stimulation of *npvf*-expressing
163 neurons promotes sleep due to release of NPVF, we optogenetically stimulated these neurons in
164 *npvf* mutant animals. Taking advantage of the transparency of zebrafish larvae, we used a
165 previously described non-invasive, large-scale assay that allows optogenetic stimulation of
166 specific neuronal populations while monitoring 96 freely-behaving animals (**Figure 4 - figure**
167 **supplement 1A,B**) (Singh et al., 2015). We first recorded baseline behavior for 30 minutes in the
168 dark, and then exposed the animals to blue light for 30 minutes. Similar to previous results using
169 animals that are homozygous wild-type for *npvf* (Lee et al., 2017), optogenetic stimulation of
170 NPVF neurons in *Tg(npvf:ReaChR-mCitrine); npvf +/-* animals resulted in reduced locomotor
171 activity and increased sleep compared to non-transgenic *npvf +/-* sibling controls (**Figure 4 -**
172 **figure supplement 1C**). In contrast, there was no significant difference between the behavior of
173 *Tg(npvf:ReaChR-mCitrine); npvf -/-* animals and their non-transgenic *npvf -/-* siblings (**Figure 4 -**
174 **figure supplement 1D**). This result indicates that sleep induced by stimulation of NPVF neurons
175 requires NPVF, and thus acts via NPVF neuropeptide/GPCR signaling.

176

177 **Sleep induced by optogenetic stimulation of *npvf*-expressing neurons requires** 178 **serotonergic RN neurons**

179 We next asked whether there is a functional interaction between *npvf*-expressing neurons and
180 the RN in promoting sleep by testing the hypothesis that NPVF neuron-induced sleep requires
181 serotonergic RN neurons. To do so, we optogenetically stimulated *npvf*-expressing neurons in
182 animals where the RN was chemogenetically ablated by enhanced nitroreductase (eNTR)
183 (Mathias et al., 2014; Tabor et al., 2014). eNTR converts the inert pro-drug metronidazole (MTZ)
184 into a cytotoxic compound that causes cell-autonomous death (Curado et al., 2007). We

185 previously showed using *Tg(tph2:eNTR-mYFP)* animals, which express eNTR-mYFP in
186 serotonergic RN neurons, that ablation of these neurons results in decreased sleep (Oikonomou
187 et al., 2019). This phenotype is similar to those of both *tph2* *-/-* zebrafish and to mice in which the
188 dorsal and median serotonergic RN are ablated (Oikonomou et al., 2019). To ask whether NPVF
189 neuron-induced sleep requires the RN, we generated *Tg(npvf:ReaChR-mCitrine); Tg(tph2:eNTR-*
190 *mYFP)* animals and asked whether the sedating effect of stimulating NPVF neurons is diminished
191 in RN ablated animals (**Figure 4A,B**). Similar to our previous report (Oikonomou et al., 2019),
192 treatment of these animals with 5 mM MTZ during 2-4 dpf resulted in near complete loss of YFP
193 fluorescence and 5-HT immunoreactivity in the RN (**Figure 4E,F**). In contrast, treatment of these
194 animals with DMSO vehicle control (**Figure 4C,D**), or treatment of *Tg(tph2:eNTR-mYFP)* negative
195 siblings with MTZ (**Figure 4G,H**), did not cause loss of the RN. We found that optogenetic
196 stimulation of MTZ-treated *Tg(npvf:ReaChR-mCitrine)* animals resulted in increased locomotor
197 activity and decreased sleep compared to identically treated non-transgenic siblings (**Figure 4I**),
198 indicating that MTZ treatment does not itself block NPVF neuron-induced sleep. In contrast, there
199 was no significant difference in the behavior of MTZ-treated *Tg(npvf:ReaChR-mCitrine);*
200 *Tg(tph2:eNTR-mYFP)* animals compared to their *Tg(tph2:eNTR-mYFP)* siblings (**Figure 4J**).
201 These results indicate that the sedating effect of stimulating *npvf*-expressing neurons requires the
202 serotonergic RN.

203

204 **Sleep induced by stimulation of *npvf*-expressing neurons requires serotonin in RN** 205 **neurons**

206 Zebrafish RN neurons produce not only serotonin, but also other factors such as GABA
207 (Kawashima et al., 2016) that may mediate NPVF neuron-induced sleep. To distinguish between
208 these possibilities, we next tested the hypothesis that NPVF neuron-induced sleep requires the
209 presence of serotonin in RN neurons. To do so, we compared the effect of optogenetic stimulation
210 of *npvf*-expressing neurons in *tph2* *-/-* animals, which do not synthesize serotonin in RN neurons

211 (Oikonomou et al., 2019), to *tph2* +/- sibling controls. Similar to previous results (Lee et al., 2017),
212 stimulation of *npvf*-expressing neurons in *Tg(npvf:ReaChR-mCitrine); tph2* +/- animals resulted
213 in decreased locomotor activity and increased sleep (**Figure 4 - figure supplement 1E**). In
214 contrast, there was no significant difference between the behavior of *Tg(npvf:ReaChR-mCitrine);*
215 *tph2* -/- animals and their non-transgenic *tph2* -/- siblings (**Figure 4 - figure supplement 1F**),
216 consistent with the hypothesis that NPVF neuron-induced sleep requires serotonin in RN neurons.

217
218 As additional confirmation that NPVF neuron-induced sleep requires serotonin in RN neurons, we
219 compared the effect of chemogenetic stimulation of *npvf*-expressing neurons in *tph2* -/- animals
220 to *tph2* +/- sibling controls (**Figure 4 – figure supplement 2**). To do so, we expressed the rat
221 capsaicin receptor TRPV1 in NPVF neurons using *Tg(npvf:KalTA4); Tg(UAS:TRPV1-tagRFP-T)*
222 animals (Lee et al., 2017). We previously showed that treating these animals with 2 μ M capsaicin,
223 a TRPV1 small molecule agonist, results in activation of NPVF neurons and increased sleep at
224 night (Lee et al., 2017). Consistent our previous observations, capsaicin-treated *Tg(npvf:KalTA4);*
225 *Tg(UAS:TRPV1-tagRFP-T); tph2* +/- animals slept more at night than their capsaicin-treated
226 *Tg(npvf:KalTA4); tph2* +/- siblings (**Figure 4 – figure supplement 2C,F**), indicating that
227 chemogenetic activation of NPVF neurons results in increased sleep at night in animals that
228 produce serotonin in the RN. However, there was no significant difference in sleep at night
229 between capsaicin-treated *Tg(npvf:KalTA4); Tg(UAS:TRPV1-tagRFP-T); tph2* -/- animals and
230 their capsaicin-treated *Tg(npvf:KalTA4); tph2* -/- siblings (**Figure 4 – figure supplement 2D,F**).
231 This result is consistent with the hypothesis that NPVF neuron-induced sleep requires serotonin
232 in RN neurons. Since 5-HT is not present in NPVF neurons (**Figure 1B-D**), our optogenetic and
233 chemogenetic data indicate that NPVF neuron-induced sleep requires serotonin in RN neurons.

234

235 **DISCUSSION**

236 The serotonergic RN were first implicated in sleep-wake regulation over 50 years ago, but it has
237 long been disputed whether they act to promote sleep or wakefulness (Ursin, 2008). We and
238 others recently addressed this controversy in both mammals and zebrafish by providing both gain-
239 and loss-of-function evidence using genetic, pharmacological, optogenetic and chemogenetic
240 approaches to demonstrate that the serotonergic RN promote sleep (Oikonomou et al., 2019;
241 Venner et al., 2019). This finding agrees with invertebrate studies which showed that 5-HT
242 signaling promotes sleep in *Drosophila* (Qian et al., 2017; Yuan et al., 2006). However, while 5-
243 HT plays an evolutionarily conserved role in promoting sleep, the neuronal mechanism that acts
244 upon serotonergic neurons to promote sleep was unknown. Here we show that *npvf*-expressing
245 neurons in the dorsomedial hypothalamus, which we previously found to be sleep-promoting in
246 zebrafish (Lee et al., 2017), densely innervate the rostral IRa, can stimulate serotonergic IRa
247 neurons, and require 5-HT in RN neurons in order to induce sleep. These results describe a
248 simple hypothalamic-hindbrain sleep-promoting neuronal circuit arising from the dorsomedial
249 hypothalamus, a region previously linked to circadian regulation of wakefulness (Chou et al.,
250 2003; Gooley et al., 2006; Mieda et al., 2006), but not to sleep. This finding suggests that re-
251 examination of hypothalamic populations using the modern tools of neuroscience may reveal
252 additional sleep- and wake-promoting populations.

253

254 We observed that stimulation of NPVF neurons results in increased GCaMP6s fluorescence in
255 most serotonergic IRa neurons, although a significant minority of IRa neurons show reduced
256 GCaMP6s fluorescence. These observations suggest that there are at least two functionally
257 distinct neuronal populations among *tph2*-expressing IRa neurons, consistent with studies of the
258 mammalian RN that identified molecularly distinct sub-populations with distinct efferent projection
259 patterns and functions (Huang et al., 2019; Ren et al., 2018; Ren et al., 2019). The NPVF neuron-
260 induced inhibition of a sub-population of IRa neurons that we observed is consistent with a
261 previous study which reported that optogenetic stimulation of NPVF neurons resulted in

262 decreased GCaMP6s fluorescence in IRa neurons (Madelaine et al., 2017), although the effect
263 was small and slow compared to our data. Further studies are needed to explore the molecular
264 and functional diversity of RN neurons in zebrafish.

265
266 The hypothalamic-hindbrain neuronal circuit that we have described can be integrated into a
267 larger sleep-promoting network. We recently reported that epidermal growth factor receptor
268 (EGFR) signaling is necessary and sufficient for normal sleep amounts in zebrafish, and that it
269 promotes sleep, in part, via the NPVF system (Lee et al., 2019). We found that it does so by both
270 promoting the expression of *npvf* and by stimulating *npvf*-expressing neurons. The EGFR ligands
271 *egf* and *transforming growth factor alpha* are expressed in glial cells in the dorsal diencephalon,
272 and *egfra*, the EGFR paralog that is primarily responsible for the role of EGFR signaling in sleep,
273 is expressed in juxta-ventricular glial cells found along the hypothalamus, hindbrain, tectum and
274 cerebellum. Taken together with the current study, these results describe a genetic and neuronal
275 circuit spanning EGFR signaling components in glial cells, *npvf*-expressing neurons in the
276 hypothalamus, and serotonergic RN neurons in the hindbrain.

277
278 If the EGFR-NPVF-RN sleep-promoting circuit plays a central and important role in regulating
279 sleep, one might expect it to be evolutionarily conserved. Indeed, similar to zebrafish, EGFR
280 signaling promotes sleep in *C. elegans* and *Drosophila* (Donlea et al., 2009; Foltenyi et al., 2007;
281 Van Buskirk and Sternberg, 2007), and genetic experiments suggest that it does so in part via
282 RFamide neuropeptides that may be invertebrate homologs of *npvf* (He et al., 2013; Iannacone
283 et al., 2017; Lenz et al., 2015; Nagy et al., 2014; Nath et al., 2016; Nelson et al., 2014; Shang et
284 al., 2013; Turek et al., 2016). Serotonin has also been shown to promote sleep in *Drosophila*
285 (Qian et al., 2017; Yuan et al., 2006), and by analogy to our results, we hypothesize that RFamide
286 neuropeptides such as FMRFamide (Lenz et al., 2015) may act upstream of 5-HT to promote
287 *Drosophila* sleep. The role of EGFR signaling in mammalian sleep is less clear.

288 Intracerebroventricular injection of epidermal growth factor (EGF) in rabbits was sufficient to
289 increase sleep (Kushikata et al., 1998), and mice containing linked mutations in *Egfr* and *Wnt3a*
290 (*Wingless integration site 3a*) showed abnormal circadian timing of sleep (Kramer et al., 2001).
291 Furthermore, pharmacological inhibition or mutation of extracellular regulated kinase (ERK),
292 which mediates EGFR signaling, was shown to result in reduced sleep in mice (Mikhail et al.,
293 2017). The spatial expression of NPVF neurons within the hypothalamus is highly conserved
294 between humans, rodents, and zebrafish (Lee et al., 2017; Liu et al., 2001; Ubuka et al., 2009;
295 Yelin-Bekerman et al., 2015), as are the expression of EGFR and its ligands in zebrafish and
296 rodent brains (Lee et al., 2019; Ma et al., 1994; Ma et al., 1992). However, NPVF has not been
297 studied in the context of mammalian sleep, so further studies are required to determine whether
298 the EGFR/NPVF/RN circuit described in zebrafish is conserved in mammals.

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314 **MATERIALS AND METHODS**

315 **KEY RESOURCE TABLE**

REAGENT TYPE or RESOURCE	Designation	SOURCE OR REFERENCE	IDENTIFIERS	ADDITIONAL INFORMATION
antibody	Rabbit polyclonal anti-5-HT antibody	MilliporeSigma	Cat# S5545; RRID:AB_477522	1:1000
antibody	Chicken anti-GFP	Aves Laboratory	Cat# GFP-1020, RRID:AB_10000240	1:1000
antibody	Rabbit anti-DsRed	Takara Bio	Cat# 632496, RRID:AB_10013483	1:1000
antibody	Rabbit anti-tagRFP	Evrogen	Cat# AB233, RRID:AB_2571743	1:200
antibody	Goat anti-Chicken IgY (H+L) Secondary Antibody, Alexa Fluor 488	ThermoFisher Sci.	Cat# A-11039; RRID: AB_2534096	1:500
antibody	Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 568	ThermoFisher Sci.	Cat# A-11011; RRID: AB_143157	1:500
antibody	Goat anti-Rat IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488	ThermoFisher Sci.	Cat# A-11006, RRID:AB_2534074	1:500
chemical compound, drug	Metronidazole	MP Biomedicals	Cat# 0215571080	
chemical compound, drug	16% paraformaldehyde	ThermoFisher Sci.	Cat# 15710	
chemical compound, drug	Normal goat serum	ThermoFisher Sci.	Cat# NC9660079	
chemical compound, drug	Collagenase	MilliporeSigma	Cat# C9891	
chemical compound, drug	Vectashield	Vector laboratories	Cat# H-1000; RRID:AB_2336789	
genetic reagent (D. rerio)	Zebrafish: <i>npvf</i> ct845 mutant	(Lee et al., 2017)	RRID: ZDB-ALT-170927-1	
genetic reagent (D. rerio)	Zebrafish: <i>tph2</i> ct817 mutant	(Chen et al., 2013a)	RRID: ZDB-ALT-131122-14	
genetic reagent (D. rerio)	Zebrafish: <i>Tg(npvf:eGFP)</i> ct847Tg	(Lee et al., 2017)	RRID: ZDB-ALT-170927-3	
genetic reagent (D. rerio)	Zebrafish: <i>Tg(npvf:GCaMP6s-tdTomato)</i> ct872Tg	(Lee et al., 2019)	ZFIN: ZDB-ALT-190725-5	
genetic reagent (D. rerio)	Zebrafish: <i>Tg(npvf:ReaChR-mCitrine)</i> ct849Tg	(Lee et al., 2017)	RRID: ZDB-ALT-170927-5	
genetic reagent (D. rerio)	Zebrafish: <i>Tg(npvf:kalta4)</i> ct848Tg	(Lee et al., 2017)	RRID: ZDB-ALT-170927-4	
genetic reagent (D. rerio)	Zebrafish: <i>Tg(tph2:eNTR-mYFP)</i> ct866Tg	(Oikonomou et al., 2019)	RRID: ZDB-ALT-190508-3	
genetic reagent (D. rerio)	Zebrafish: <i>Tg(tph2:GCaMP6s-tdTomato)</i>	This study		
genetic reagent (D. rerio)	Zebrafish: <i>Tg(UAS:nfsb-mCherry)</i> rw0144Tg	(Agetsuma et al., 2010)	ZFIN: ZDB-ALT-110215-7	
genetic reagent (D. rerio)	Zebrafish: <i>Tg(UAS:TRPV1-tagRFP-T)</i> ct851Tg	(Lee et al., 2017)	RRID: ZDB-ALT-170927-7	
sequence-based reagent	Primer: <i>tph2</i> mutant genotyping primer 1: AGAACTTACAAAACCTATCCAACCTC	(Oikonomou et al., 2019)	N/A	
sequence-based reagent	Primer: <i>tph2</i> mutant genotyping primer 2: AGAGAGGACAACATCTGGGG	(Oikonomou et al., 2019)	N/A	
sequence-based reagent	Primer: <i>tph2</i> mutant genotyping primer 3: TAATCATGCAGTCCGTTAATACTC	(Oikonomou et al., 2019)	N/A	
sequence-based reagent	Primer: <i>npvf</i> mutant genotyping primer 1: CAGTGGTGGTGCGAGTTCT	(Lee et al., 2017)	N/A	
sequence-based reagent	Primer: <i>npvf</i> mutant genotyping primer 2: GCTGAGGGAGGTTGATGGTA	(Lee et al., 2017)	N/A	

sequence-based reagent	Primer: <i>Tg(npvf:ReaChR-mCitrine)</i> genotyping primer 1: CACGAGAGAATGCTGTTCCA	(Lee et al., 2017)	N/A	
sequence-based reagent	Primer: <i>Tg(npvf:ReaChR-mCitrine)</i> genotyping primer 2: CCATGGTGCGTTTGCTATAA	(Lee et al., 2017)	N/A	
sequence-based reagent	Primer: <i>Tg(UAS:TRPV1-tagRFP-T)</i> genotyping primer 1: CAGCCTCACTTTGAGCTCCT:	(Lee et al., 2017)	N/A	
sequence-based reagent	Primer: <i>Tg(UAS:TRPV1-tagRFP-T)</i> genotyping primer 2: TCCTCATAAGGGCAGTCCAG	(Lee et al., 2017)	N/A	
software	MATLAB R2017b	Mathworks	RRID:SCR_001622	
software	Prism6	GraphPad	RRID:SCR_002798	
software	Image J/Fiji	(Schneider et al., 2012)	RRID:SCR_002285	
other	96-well plate	GE Healthcare Life Sciences	Cat#:7701-1651	
other	MicroAmp Optical Adhesive Film	Thermo Fisher Scientific	Cat#: 4311971	

316

317

318 EXPERIMENTAL MODEL AND SUBJECT DETAILS

319 Animal husbandry and all experimental procedures involving zebrafish were performed in
320 accordance with the California Institute of Technology Institutional Animal Care and Use
321 Committee (IACUC) guidelines and by the Office of Laboratory Animal Resources at the California
322 Institute of Technology (animal protocol 1580). All experiments used zebrafish between 5 and 6
323 dpf. Sex is not yet defined at this stage of development. Larvae were housed in petri dishes with
324 50 animals per dish. E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl₂, 0.33 mM MgSO₄)
325 was used for housing and experiments. All lines were derived from the TLAB hybrid strain. Unless
326 otherwise indicated, for experiments using mutant animals, heterozygous and homozygous
327 mutant adult animals were mated, and their homozygous mutant and heterozygous mutant
328 progeny were compared to each other to minimize variation due to genetic background. For
329 experiments using transgenic animals, heterozygous transgenic animals were outcrossed to non-
330 transgenic animals of the parental TLAB strain, and transgenic heterozygote progeny were
331 compared to their non-transgenic siblings. Behavioral experiments were performed unbiased to
332 genotype, with animals genotyped by PCR after each experiment was complete.

333

334 **Transgenic and mutant animals**

335 The *Tg(npvf:eGFP)* ct847Tg (Lee et al., 2017), *Tg(npvf:ReaChR-mCitrine)* ct849Tg (Lee et al.,
336 2017), *Tg(npvf:kalta4)* ct848Tg (Lee et al., 2017), *Tg(tph2:eNTR-mYFP)* ct866Tg (Oikonomou et
337 al., 2019), *Tg(UAS:nfsb-mCherry)* rw0144Tg (Agetsuma et al., 2010), *Tg(UAS:TRPV1-tagRFP-*
338 *T)* ct851Tg (Lee et al., 2017), *npvf* ct845 mutant (Lee et al., 2017), and *tph2* ct817 mutant (Chen
339 et al., 2013a) lines have been previously described.

340

341 To generate the *Tg(tph2:GCaMP6s-P2A-NLS-tdTomato)* line we cloned the *tph2* promoter
342 (Oikonomou et al., 2019) upstream of GCaMP6s (Chen et al., 2013b) followed by a P2A
343 sequence, which generates a self-cleaving peptide (Kim et al., 2011), and NLS-tdTomato. Stable
344 transgenic lines were generated using the Tol2 method (Urasaki et al., 2006).

345

346 **Immunohistochemistry**

347 Samples were fixed in 4% PFA/4% sucrose in PBS overnight at 4°C and then washed with 0.25%
348 Triton X-100/PBS (PBTx). Immunolabeling was performed using dissected brains because this
349 allows for superior antibody penetration. Dissected brains were incubated for 1 hour in 1 mg/mL
350 collagenase (C9891, MilliporeSigma, St. Louis, Missouri, USA) and blocked overnight in 2%
351 NGS/2% DMSO in PBTx at 4°C. Incubation with rabbit anti-5-HT (1:1000; S5545, MilliporeSigma,
352 Burlington, MA, USA), chicken anti-GFP (1:1000, GFP-1020, Aves Laboratory, Davis, CA, USA),
353 and rabbit anti-DsRed (1:1000, Takara Bio, Mountainview, CA, USA) primary antibodies was
354 performed in blocking solution overnight at 4°C. Incubation with goat anti-rabbit IgG Alexa Fluor
355 568, goat anti-chicken IgY Alexa Fluor 488, and goat anti-rat IgG Alexa Fluor 488 (all 1:500,
356 ThermoFisher Sci., Waltham, MA, USA) secondary antibodies was performed in blocking solution
357 overnight at 4°C. Samples were mounted in Vectashield (H-1000; Vector Laboratories,
358 Burlingame, CA, USA) and imaged using a Zeiss LSM 880 confocal microscope (Zeiss,
359 Oberkochen, Germany).

360

361 **Two-photon optogenetic stimulation and GCaMP6s imaging**

362 At 6 dpf, animals were paralyzed by immersion in 1 mg/ml α -bungarotoxin (2133, Tocris, Bristol,
363 UK) dissolved in E3, embedded in 1.5% low melting agarose (EC-202, National Diagnostics,
364 Atlanta, GA, United States) and imaged using a 20x water immersion objective on a Zeiss LSM
365 880 microscope equipped with a two-photon laser (Chameleon Coherent, Wilsonville, OR, USA).
366 Laser power coming out of the objective was quantified using a power meter (PM121D, ThorLabs,
367 Newton, NJ, USA). For GCaMP6s imaging, a region of interest (ROI) that encompassed the *npvf*-
368 or *tph2*-expressing neuronal somas was defined based on nuclear localized tdTomato, which was
369 stoichiometrically co-expressed with GCaMP6s. GCaMP6s fluorescence intensity was quantified
370 using Image J (Schneider et al., 2012). **Figure 2 – figure supplement 1F** provides an example
371 of how ROI were defined. GCaMP6s fluorescence was excited using a 920 nm two-photon laser
372 (Chameleon Coherent, Wilsonville, OR, USA) at 8 mW, imaged in a 512 x 256 pixel frame (1.27
373 s per frame, pixel size=0.55 μ m, pixel dwell time=2.07 μ s) for 150 frames (190.5 s). For
374 optogenetic stimulation of NPVF neurons, a 150 x 100 pixel region that encompassed the NPVF
375 neuronal somas was illuminated using the 920 nm two-photon laser at 38 mW. Ten pulses were
376 applied over 3.72 s using the bleaching function at 2.7 Hz per pixel. The time between the final
377 stimulation pulse and initiation of post-stimulation imaging was 0.6 s, and was due to the computer
378 registering coordinate information with the scan device (~0.4 s) and for the non-descanned
379 detector to turn off (~0.2 s). GCaMP6s fluorescence was then imaged again for another 150
380 frames before another stimulation trial. Three stimulation trials were performed on each fish, and
381 the average value from these trials was calculated for each neuron. Baseline fluorescence (F_0)
382 for each trial was defined as the average value from 30 frames immediately preceding the
383 stimulation, and 35 (**Figure 2D-F**) or 30 (**Figure 2 – figure supplement 1G-I**) frames post
384 stimulation were used to measure the normalized change in fluorescence ($\Delta F/F = (F - F_0)/(F_0 -$

385 $F_{\text{background}}$). $F_{\text{background}}$ was defined by average fluorescence intensity during 30 frames prior to
386 optogenetic stimulation in a GCaMP-negative background region approximately 40 μm from the
387 nearest NPVF neuronal soma. Five *Tg(npvf:ReaChR);Tg(npvf:GCaMP6s-tdTomato)* animals,
388 with approximately 17 NPVF neurons per animal, were analyzed for **Figure 2 – figure**
389 **supplement 1**. Data from four *Tg(npvf:ReaChR);Tg(tph2:GCaMP6s-tdTomato)* and four
390 *Tg(npvf:eGFP);Tg(tph2:GCaMP6s-tdTomato)* animals, with approximately 30 IRa neurons
391 analyzed per animal, is shown in **Figure 2 – figure supplement 1**.

392

393 **Sleep/wake behavioral analysis**

394 Sleep/wake analysis was performed as previously described (Chiu et al., 2016). Larvae were
395 raised on a 14:10 h light:dark (LD) cycle at 28.5°C with lights on at 9 a.m. and off at 11 p.m. Dim
396 white light was used to raise larvae for optogenetic experiments to prevent stimulation of ReaChR
397 by ambient light. Individual larvae were placed into each well of a 96-well plate (7701-1651,
398 Whatman, Pittsburgh, PA, United States) containing 650 μl of E3 embryo medium. Locomotor
399 activity was monitored using a videotracking system (Viewpoint Life Sciences, Lyon, France) with
400 a Dinion one-third inch Monochrome camera (Dragonfly 2, Point Grey, Richmond, Canada) fitted
401 with a variable-focus megapixel lens (M5018-MP, Computar, Cary, NC, United States) and
402 infrared filter. The movement of each larva was recorded using the quantization mode. The 96-
403 well plate and camera were housed inside a custom-modified Zebrabox (Viewpoint Life Sciences)
404 that was continuously illuminated with infrared light. The 96-well plate was housed in a chamber
405 filled with recirculating water to maintain a constant temperature of 28.5°C. The parameters used
406 for movement detection were: detection threshold, 15; burst, 29; freeze, 3; bin size, 60 s, which
407 were determined empirically. Data were analyzed using custom Perl and Matlab (Mathworks,
408 Natick, MA, United States) scripts, which conform to the open source definition.

409

410 **Optogenetic stimulation of freely behaving animals**

411 Optogenetic behavioral experiments were performed as described (Singh et al., 2015). These
412 experiments used a videotracking system with a custom array containing three sets of blue LEDs
413 (470 nm, MR-B0040-10S, Luxeon V-star, Brantford, Canada) mounted 15 cm above and 7 cm
414 away from the center of the 96-well plate to ensure uniform illumination. The LEDs were controlled
415 using a custom-built driver and software written in BASIC stamp editor. A power meter (1098293,
416 Laser-check, Santa Clara, CA, USA) was used before each experiment to verify uniform light
417 intensity (~400 μ W at the surface of the 96-well plate). In the afternoon of the fifth day of
418 development, single larvae were placed into each well of a 96-well plate and placed in the
419 videotracker in the dark. Larvae were exposed to blue light for 30 minutes for each of 3 trials
420 beginning at 12:30 am, 3:00 am, 5:30 am. Behavior was monitored for 30 minutes before and
421 after light onset. Light onset induces a startle response, which causes a short burst of locomotor
422 activity. For this reason, we excluded five minutes of behavioral recording centered at the peak
423 of blue light onset from analysis. Data was normalized by dividing the locomotor activity or sleep
424 of each animal during light exposure by the average baseline locomotor activity or sleep of all
425 animals of the same genotype. For baseline, we used a time period equal in length to blue light
426 exposure, but prior to light onset.

427

428 **Chemogenetic ablation**

429 Animals were treated with 5 mM metronidazole (MTZ) (0215571080, MP Biomedicals, Santa Ana,
430 CA, USA) diluted in E3 medium containing 0.1% DMSO, starting in the afternoon at 2 dpf, and
431 refreshed every 24 hours. Animals were kept in dim light during the day to prevent MTZ
432 photodegradation. On the evening at 4-dpf, the animals were rinsed 3 times in E3 medium, moved
433 into petri dishes to allow for recovery overnight, and then transferred to 96-well plates on the
434 morning of 5-dpf. Reported data is from the 5th night of development.

435

436 **Chemogenetic stimulation**

437 Neuronal activation using TRPV1 was performed as described (Lee et al., 2017) with some
438 modifications. *Tg(npvf:KalTA4); tph2+/-*, *Tg(npvf:KalTA4); tph2-/-*, *Tg(npvf:KalTA4);*
439 *Tg(UAS:TRPV1-tagRFP-T); tph2+/-*, and *Tg(npvf:KalTA4);Tg(UAS:TRPV1-tagRFP-T); tph2-/-*
440 siblings were immersed in 2 μ M capsaicin at ~100 h post-fertilization (hpf). Capsaicin powder
441 (M2028, Sigma, St. Louis, Missouri, USA) was dissolved in DMSO to prepare a 100 mM stock
442 solution that was stored in aliquots at -20 °C. Capsaicin working solutions were prepared just
443 before each experiment by diluting the stock solution in E3 medium. All treatments contained a
444 final concentration of 0.002% DMSO. Behavioral analysis was performed from 5 dpf until 6 dpf
445 blinded to the genotype.

446

447 **QUANTIFICATION AND STATISTICAL ANALYSIS**

448 For all behavioral experiments the unit of analysis for statistics is a single animal. For optogenetic
449 imaging experiments, the unit of analysis for statistics is the average of three optogenetic
450 stimulation trials for a single neuron. The number of neurons and animals whose data are shown
451 in a panel are either shown in the figure or stated in the figure legend. Line graphs in **Figure 3A-**
452 **D** and **Figure 4 – figure supplement 2A-D** represent mean, and were generated from raw data
453 that was smoothed over 1 hour bins in 10 minute intervals. The significance threshold was set to
454 $P < 0.05$, and P values were adjusted for multiple comparisons where appropriate. Normality tests
455 (D'Agostino & Pearson omnibus normality test) found that most datasets were not normally
456 distributed so we used non-parametric tests for statistical analyses (Mann-Whitney test for two
457 unpaired groups). For comparison of differences between groups with two-factor designs, we
458 used Two-Way ANOVA with Holm-Sidak correction for multiple comparisons (**Figure 3,4**).
459 Normality tests (D'Agostino & Pearson omnibus normality test) for the data in **Figures 3** and
460 **Figure 4 – figure supplement 2** demonstrated that half of values were normally distributed,
461 suggesting that Two-Way ANOVA would be an appropriate statistical test; ANOVA analyses are
462 robust to even large deviation from normality when samples sizes are appropriately large enough.

463 For box plots, the box extends from the 25th to the 75th percentile with the median marked by a
464 horizontal line through the box. The lower and upper whiskers extend to the 10th and 90th
465 percentile, respectively. Data points outside the lower and upper whiskers were not shown in the
466 graphs to facilitate data presentation but were included in statistical analyses. Statistical analyses
467 were performed using Prism 6 (GraphPad Software, San Diego, CA, USA).

468

469 **DATA AND CODE AVAILABILITY**

470 Source code data used to generate most figures are publicly available at
471 <https://elifesciences.org/articles/25727> (Lee et al., 2017). All input data used to generate most
472 figures is available as source data associated with this manuscript.

473

474 **Figure 1-Source Data 1:** Confocal stack of a brain from a 6-dpf *Tg(npvf:eGFP)* animal
475 immunostained against eGFP and 5-HT.

476

477 **Figure 1-Supplement1-Source Data 1:** Confocal stacks of a brain from a 6-dpf
478 *Tg(npvf:KalTA4);Tg(uas:nfsb-mCherry);Tg(tph2:eNTR-mYFP)* animal immunostained against
479 YFP and mCherry.

480

481 **Figure 2-Source Data 1: (A)** Confocal image of a live 6-dpf *Tg(npvf:ReaChR-mCitrine);*
482 *Tg(tph2:GCaMP6s-tdTomato)* animal showing GCaMP6s and tdTomato fluorescence in IRa
483 neurons. Green and magenta fluorescence in the eyes is due to autofluorescence. **(C)** Average
484 GCaMP6s fluorescence in IRa neurons for 10 frames before (Pre) and after (Post) optogenetic
485 stimulation of NPVF neurons. **(D,E)** Input data and statistical analysis for GCaMP6s fluorescence
486 of IRa neurons plotted as a function of time, showing pre-stimulation and post-stimulation evoked
487 responses for *Tg(tph2:GCaMP6s-tdTomato)* animals that also contain a *Tg(npvf:eGFP)* **(D,F)** or
488 *Tg(npvf:ReaChR-mCitrine)*.

489

490 **Figure 2-Supplement1-Source Data 1: (A)** Confocal image of a live 6-dpf *Tg(npvf:ReaChR);*
491 *Tg(npvf:GCaMP6s-tdTomato)* animal showing GCaMP6s and tdTomato fluorescence in NPVF
492 neurons. Green and magenta fluorescence in the eyes is due to autofluorescence. **(H)** GCaMP6s
493 and mCitrine $\Delta F/F$ values for individual NPVF neurons (86 neurons, 5 animals) are plotted as
494 function of time, showing pre-stimulation and post-stimulation evoked responses. **(I)** Statistical
495 analysis for GCaMP6s and mCitrine $\Delta F/F$ values one frame after stimulation for
496 *Tg(npvf:GCaMP6s-tdTomato)* animals that also contain a *Tg(npvf:ReaChR)* (blue) or
497 *Tg(npvf:eGFP)* (black) transgene. n=number of neurons.

498

499 **Figure 3-Source Data 1:** Input data and statistical analysis for the average sleep for *npvf +/-;*
500 *tph2 +/-, npvf -/-; tph2 +/-, npvf +/-; tph2 -/-, and npvf -/-; tph2 -/-* siblings.

501

502 **Figure 4-Source Data 1: (B)** Confocal image of an immunostained 5-dpf *Tg(tph2:eNTR-mYFP)*
503 zebrafish brain showing serotonergic RN neurons and some of their projections and labeled with
504 a 5-HT specific antibody. **(I-J)** Input data and statistical analysis for normalized locomotor activity
505 and sleep of 5-dpf *Tg(npvf:ReaChR)* and non-transgenic sibling controls (black and gray)
506 zebrafish before (Baseline) and during blue light exposure (Stimulation) in *Tg(tph2:eNTR)*
507 negative animals **(I)** and in *Tg(tph2:eNTR)* positive siblings **(J)**. Box plots quantify locomotor
508 activity and sleep during optogenetic stimulation normalized to baseline of the same genotype.
509 n=number of animals.

510

511 **Figure 4-Supplement1-Source Data 1: (A)** Confocal image of a live 5-dpf *Tg(npvf:ReaChR-*
512 *mCitrine)* animal. NPVF neurons in the hypothalamus are labeled with the *npvf:ReaChR-mCitrine*
513 transgene. Green fluorescence in the eyes is due to autofluorescence. **(C,D)** Input data and
514 statistical analysis for normalized locomotor activity and sleep of *Tg(npvf:ReaChR)* and non-

515 transgenic sibling control animals before (Baseline) and during exposure to blue light (Stimulation)
516 in *npvf +/-* (**C**) and *npvf -/-* (**D**) animals. (**E,F**) Same as (**C,D**) but with *tph2* mutant rather than *npvf*
517 mutant. Because the animals see the blue light, they exhibit a brief startle at light onset that is
518 excluded from analysis, followed by a gradual increase in activity that plateaus after ~15 minutes.
519 Box plots quantify locomotor activity and sleep for each animal during optogenetic stimulation
520 normalized to the baseline of all animals the same genotype. Stimulation of *npvf*-expressing
521 neurons decreases locomotor activity and increases sleep compared to non-transgenic sibling
522 controls in *npvf +/-* animals (**C**) but not in *npvf -/-* siblings (**D**), and in *tph2 +/-* animals (**E**) but not
523 in *tph2 -/-* siblings (**F**). n=number of animals.

524

525 **Figure 4-Supplement2-Source Data 2: (A)** Input data and statistical analysis for sleep
526 associated with 5-6dpf *Tg(npvf:KalTA4); tph2+/-, Tg(npvf:KalTA4);tph2-/-,*
527 *Tg(npvf:KalTA4);Tg(UAS:TRPV1-TagRFP-T);tph2+/-,* and *Tg(npvf:KalTA4);Tg(UAS:TRPV1-*
528 *TagRFP-T);tph2-/-* (light blue) siblings treated with 2 μ M capsaicin.

529

530

531

532

533

534

535

536

537

538

539

540

541 **ACKNOWLEDGEMENTS**

542 We thank members of the Prober lab for helpful discussions; Uyen Pham, Chris Cook, and
543 Hannah Hurley for zebrafish husbandry assistance; and Andres Collazo, Giada Spigolon, Andrey
544 Andreev and the Beckman Institute Biological Imaging Facility for 2-photon imaging assistance.
545 This work was supported by grants from the NIH (DAL: K99NS097683, F32NS084769; GO:
546 F32NS084769; DAP: NS070911, NS101158), a NARSAD Young Investigator Grant (DAL: 25392)
547 and a Caltech BBE Postdoctoral Fellowship to DAL. The authors declare no competing interests.

548

549

550 **AUTHOR CONTRIBUTIONS**

551 DAL and DAP designed experiments. DAL, TC and YH performed experiments and analysis. GO
552 generated *tph2* transgenic animals and Matlab code. DAP supervised the project. DAL and DAP
553 wrote the paper with input from GO.

554

555 **AUTHOR ORCIDs**

556 Daniel A Lee, <http://orcid.org/0000-0001-7411-2740>

557 Grigorios Oikonomou, <http://orcid.org/0000-0001-6797-7375>

558 David A Prober, <http://orcid.org/0000-0002-7371-4675>

559

560 **ETHICS**

561 Animal experimentation: This study was performed in strict accordance with the recommendations
562 in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All
563 experiments were performed using standard protocols (Westerfield, 1993) in accordance with the
564 California Institute of Technology Institutional Animal Care and Use Committee guidelines.

565 **REFERENCES**

566

567 Agetsuma, M., Aizawa, H., Aoki, T., Nakayama, R., Takahoko, M., Goto, M., Sassa, T., Amo,
568 R., Shiraki, T., Kawakami, K., *et al.* (2010). The habenula is crucial for experience-dependent
569 modification of fear responses in zebrafish. *Nat Neurosci* 13, 1354-1356.

570 Bringmann, H. (2018). Sleep-Active Neurons: Conserved Motors of Sleep. *Genetics* 208, 1279-
571 1289.

572 Chen, S., Oikonomou, G., Chiu, C.N., Niles, B.J., Liu, J., Lee, D.A., Antoshechkin, I., and
573 Prober, D.A. (2013a). A large-scale in vivo analysis reveals that TALENs are significantly more
574 mutagenic than ZFNs generated using context-dependent assembly. *Nucleic acids research* 41,
575 2769-2778.

576 Chen, T.W., Wardill, T.J., Sun, Y., Pulver, S.R., Renninger, S.L., Baohan, A., Schreiter, E.R.,
577 Kerr, R.A., Orger, M.B., Jayaraman, V., *et al.* (2013b). Ultrasensitive fluorescent proteins for
578 imaging neuronal activity. *Nature* 499, 295-300.

579 Cheng, R.K., Krishnan, S., and Jesuthasan, S. (2016). Activation and inhibition of tph2
580 serotonergic neurons operate in tandem to influence larval zebrafish preference for light over
581 darkness. *Sci Rep* 6, 20788.

582 Chiu, C.N., Rihel, J., Lee, D.A., Singh, C., Mosser, E.A., Chen, S., Sapin, V., Pham, U., Engle,
583 J., Niles, B.J., *et al.* (2016). A Zebrafish Genetic Screen Identifies Neuromedin U as a Regulator
584 of Sleep/Wake States. *Neuron* 89, 842-856.

- 585 Chou, T.C., Scammell, T.E., Gooley, J.J., Gaus, S.E., Saper, C.B., and Lu, J. (2003). Critical
586 role of dorsomedial hypothalamic nucleus in a wide range of behavioral circadian rhythms. *J*
587 *Neurosci* 23, 10691-10702.
- 588 Curado, S., Anderson, R.M., Jungblut, B., Mumm, J., Schroeter, E., and Stainier, D.Y. (2007).
589 Conditional targeted cell ablation in zebrafish: a new tool for regeneration studies. *Dev Dyn* 236,
590 1025-1035.
- 591 Dahlstroem, A., and Fuxe, K. (1964). Evidence for the Existence of Monoamine-Containing
592 Neurons in the Central Nervous System. I. Demonstration of Monoamines in the Cell Bodies of
593 Brain Stem Neurons. *Acta Physiol Scand Suppl*, SUPPL 232:231-255.
- 594 Donlea, J.M., Ramanan, N., and Shaw, P.J. (2009). Use-dependent plasticity in clock neurons
595 regulates sleep need in *Drosophila*. *Science* 324, 105-108.
- 596 Foltenyi, K., Greenspan, R.J., and Newport, J.W. (2007). Activation of EGFR and ERK by
597 rhomboid signaling regulates the consolidation and maintenance of sleep in *Drosophila*. *Nat*
598 *Neurosci* 10, 1160-1167.
- 599 Gooley, J.J., Schomer, A., and Saper, C.B. (2006). The dorsomedial hypothalamic nucleus is
600 critical for the expression of food-entrainable circadian rhythms. *Nat Neurosci* 9, 398-407.
- 601 He, C., Yang, Y., Zhang, M., Price, J.L., and Zhao, Z. (2013). Regulation of sleep by
602 neuropeptide Y-like system in *Drosophila melanogaster*. *PLoS One* 8, e74237.

- 603 Hinuma, S., Shintani, Y., Fukusumi, S., Iijima, N., Matsumoto, Y., Hosoya, M., Fujii, R.,
604 Watanabe, T., Kikuchi, K., Terao, Y., *et al.* (2000). New neuropeptides containing carboxy-
605 terminal RFamide and their receptor in mammals. *Nat Cell Biol* 2, 703-708.
- 606 Huang, K.W., Ochandarena, N.E., Philson, A.C., Hyun, M., Birnbaum, J.E., Cicconet, M., and
607 Sabatini, B.L. (2019). Molecular and anatomical organization of the dorsal raphe nucleus. *Elife*
608 8.
- 609 Iannacone, M.J., Beets, I., Lopes, L.E., Churgin, M.A., Fang-Yen, C., Nelson, M.D., Schoofs, L.,
610 and Raizen, D.M. (2017). The RFamide receptor DMSR-1 regulates stress-induced sleep in *C.*
611 *elegans*. *Elife* 6.
- 612 Kawashima, T., Zwart, M.F., Yang, C.T., Menseh, B.D., and Ahrens, M.B. (2016). The
613 Serotonergic System Tracks the Outcomes of Actions to Mediate Short-Term Motor Learning.
614 *Cell* 167, 933-946 e920.
- 615 Kim, J.H., Lee, S.R., Li, L.H., Park, H.J., Park, J.H., Lee, K.Y., Kim, M.K., Shin, B.A., and Choi,
616 S.Y. (2011). High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in
617 human cell lines, zebrafish and mice. *PLoS One* 6, e18556.
- 618 Kramer, A., Yang, F.C., Snodgrass, P., Li, X., Scammell, T.E., Davis, F.C., and Weitz, C.J.
619 (2001). Regulation of daily locomotor activity and sleep by hypothalamic EGF receptor
620 signaling. *Science* 294, 2511-2515.
- 621 Kushikata, T., Fang, J., Chen, Z., Wang, Y., and Krueger, J.M. (1998). Epidermal growth factor
622 enhances spontaneous sleep in rabbits. *Am J Physiol* 275, R509-514.

- 623 Lee, D.A., Andreev, A., Truong, T.V., Chen, A., Hill, A.J., Oikonomou, G., Pham, U., Hong, Y.K.,
624 Tran, S., Glass, L., *et al.* (2017). Genetic and neuronal regulation of sleep by neuropeptide VF.
625 *Elife* 6.
- 626 Lee, D.A., Liu, J., Hong, Y., Hou, S., Hill, A.J., Lane, J.M., Wang, H., Oikonomou, G., Pham, U.,
627 Engle, J., *et al.* (2019). Evolutionarily Conserved Regulation of Sleep by Epidermal Growth
628 Factor Receptor Signaling. *Science Advances* 5.
- 629 Lenz, O., Xiong, J., Nelson, M.D., Raizen, D.M., and Williams, J.A. (2015). FMRFamide
630 signaling promotes stress-induced sleep in *Drosophila*. *Brain Behav Immun* 47, 141-148.
- 631 Lillesaar, C., Stigloher, C., Tannhauser, B., Wullimann, M.F., and Bally-Cuif, L. (2009). Axonal
632 projections originating from raphe serotonergic neurons in the developing and adult zebrafish,
633 *Danio rerio*, using transgenics to visualize raphe-specific *pet1* expression. *J Comp Neurol* 512,
634 158-182.
- 635 Liu, D., and Dan, Y. (2019). A Motor Theory of Sleep-Wake Control: Arousal-Action Circuit.
636 *Annu Rev Neurosci* 42, 27-46.
- 637 Liu, Q., Guan, X.M., Martin, W.J., McDonald, T.P., Clements, M.K., Jiang, Q., Zeng, Z.,
638 Jacobson, M., Williams, D.L., Jr., Yu, H., *et al.* (2001). Identification and characterization of
639 novel mammalian neuropeptide FF-like peptides that attenuate morphine-induced
640 antinociception. *J Biol Chem* 276, 36961-36969.

- 641 Ma, Y.J., Hill, D.F., Junier, M.P., Costa, M.E., Felder, S.E., and Ojeda, S.R. (1994). Expression
642 of epidermal growth factor receptor changes in the hypothalamus during the onset of female
643 puberty. *Mol Cell Neurosci* 5, 246-262.
- 644 Ma, Y.J., Junier, M.P., Costa, M.E., and Ojeda, S.R. (1992). Transforming growth factor-alpha
645 gene expression in the hypothalamus is developmentally regulated and linked to sexual
646 maturation. *Neuron* 9, 657-670.
- 647 Madelaine, R., Lovett-Barron, M., Halluin, C., Andalman, A.S., Liang, J., Skariah, G.M., Leung,
648 L.C., Burns, V.M., and Mourrain, P. (2017). The hypothalamic NPVF circuit modulates ventral
649 raphe activity during nociception. *Sci Rep* 7, 41528.
- 650 Mathias, J.R., Zhang, Z., Saxena, M.T., and Mumm, J.S. (2014). Enhanced cell-specific ablation
651 in zebrafish using a triple mutant of *Escherichia coli* nitroreductase. *Zebrafish* 11, 85-97.
- 652 Mieda, M., Williams, S.C., Richardson, J.A., Tanaka, K., and Yanagisawa, M. (2006). The
653 dorsomedial hypothalamic nucleus as a putative food-entrainable circadian pacemaker. *Proc*
654 *Natl Acad Sci U S A* 103, 12150-12155.
- 655 Mikhail, C., Vaucher, A., Jimenez, S., and Tafti, M. (2017). ERK signaling pathway regulates
656 sleep duration through activity-induced gene expression during wakefulness. *Sci Signal* 10.
- 657 Nagy, S., Tramm, N., Sanders, J., Iwanir, S., Shirley, I.A., Levine, E., and Biron, D. (2014).
658 Homeostasis in *C. elegans* sleep is characterized by two behaviorally and genetically distinct
659 mechanisms. *Elife* 3, e04380.

- 660 Nath, R.D., Chow, E.S., Wang, H., Schwarz, E.M., and Sternberg, P.W. (2016). *C. elegans*
661 Stress-Induced Sleep Emerges from the Collective Action of Multiple Neuropeptides. *Curr Biol*
662 26, 2446-2455.
- 663 Nelson, M.D., Lee, K.H., Churgin, M.A., Hill, A.J., Van Buskirk, C., Fang-Yen, C., and Raizen,
664 D.M. (2014). FMRamide-like FLP-13 neuropeptides promote quiescence following heat stress
665 in *Caenorhabditis elegans*. *Curr Biol* 24, 2406-2410.
- 666 Oikonomou, G., Altermatt, M., Zhang, R.W., Coughlin, G.M., Montz, C., Gradinaru, V., and
667 Prober, D.A. (2019). The Serotonergic Raphe Promote Sleep in Zebrafish and Mice. *Neuron*
668 103, 686-701 e688.
- 669 Oikonomou, G., and Prober, D.A. (2017). Attacking sleep from a new angle: contributions from
670 zebrafish. *Curr Opin Neurobiol* 44, 80-88.
- 671 Pollak Dorocic, I., Furth, D., Xuan, Y., Johansson, Y., Pozzi, L., Silberberg, G., Carlen, M., and
672 Meletis, K. (2014). A whole-brain atlas of inputs to serotonergic neurons of the dorsal and
673 median raphe nuclei. *Neuron* 83, 663-678.
- 674 Qian, Y., Cao, Y., Deng, B., Yang, G., Li, J., Xu, R., Zhang, D., Huang, J., and Rao, Y. (2017).
675 Sleep homeostasis regulated by 5HT2b receptor in a small subset of neurons in the dorsal fan-
676 shaped body of *Drosophila*. *Elife* 6.
- 677 Ren, J., Friedmann, D., Xiong, J., Liu, C.D., Ferguson, B.R., Weerakkody, T., DeLoach, K.E.,
678 Ran, C., Pun, A., Sun, Y., *et al.* (2018). Anatomically Defined and Functionally Distinct Dorsal
679 Raphe Serotonin Sub-systems. *Cell* 175, 472-487 e420.

- 680 Ren, J., Isakova, A., Friedmann, D., Zeng, J., Grutzner, S.M., Pun, A., Zhao, G.Q., Kolluru, S.S.,
681 Wang, R., Lin, R., *et al.* (2019). Single-cell transcriptomes and whole-brain projections of
682 serotonin neurons in the mouse dorsal and median raphe nuclei. *Elife* 8.
- 683 Saper, C.B., and Fuller, P.M. (2017). Wake-sleep circuitry: an overview. *Curr Opin Neurobiol* 44,
684 186-192.
- 685 Scammell, T.E., Arrigoni, E., and Lipton, J.O. (2017). Neural Circuitry of Wakefulness and
686 Sleep. *Neuron* 93, 747-765.
- 687 Schneider, C.A., Rasband, W.S., and Eliceiri, K.W. (2012). NIH Image to ImageJ: 25 years of
688 image analysis. *Nat Methods* 9, 671-675.
- 689 Shang, Y., Donelson, N.C., Vecsey, C.G., Guo, F., Rosbash, M., and Griffith, L.C. (2013). Short
690 neuropeptide F is a sleep-promoting inhibitory modulator. *Neuron* 80, 171-183.
- 691 Singh, C., Oikonomou, G., and Prober, D.A. (2015). Norepinephrine is required to promote
692 wakefulness and for hypocretin-induced arousal in zebrafish. *Elife* 4.
- 693 Tabor, K.M., Bergeron, S.A., Horstick, E.J., Jordan, D.C., Aho, V., Porkka-Heiskanen, T.,
694 Haspel, G., and Burgess, H.A. (2014). Direct activation of the Mauthner cell by electric field
695 pulses drives ultrarapid escape responses. *J Neurophysiol* 112, 834-844.
- 696 Turek, M., Besseling, J., Spies, J.P., Konig, S., and Bringmann, H. (2016). Sleep-active neuron
697 specification and sleep induction require FLP-11 neuropeptides to systemically induce sleep.
698 *Elife* 5.

- 699 Ubuka, T., Morgan, K., Pawson, A.J., Osugi, T., Chowdhury, V.S., Minakata, H., Tsutsui, K.,
700 Millar, R.P., and Bentley, G.E. (2009). Identification of human GnIH homologs, RFRP-1 and
701 RFRP-3, and the cognate receptor, GPR147 in the human hypothalamic pituitary axis. *PLoS*
702 *One* 4, e8400.
- 703 Urasaki, A., Morvan, G., and Kawakami, K. (2006). Functional dissection of the Tol2
704 transposable element identified the minimal cis-sequence and a highly repetitive sequence in
705 the subterminal region essential for transposition. *Genetics* 174, 639-649.
- 706 Ursin, R. (2008). Changing concepts on the role of serotonin in the regulation of sleep and
707 waking. In *Serotonin and Sleep: Molecular, Functional and Clinical Aspects* J.M. Monti, S.R.
708 Pandi-Perumal, B.L. Jacobs, and D.J. Nutt, eds. (Switzerland: Birkhäuser Basel).
- 709 Van Buskirk, C., and Sternberg, P.W. (2007). Epidermal growth factor signaling induces
710 behavioral quiescence in *Caenorhabditis elegans*. *Nat Neurosci* 10, 1300-1307.
- 711 van den Pol, A.N. (2012). Neuropeptide transmission in brain circuits. *Neuron* 76, 98-115.
- 712 Venner, A., Broadhurst, R.Y., Sohn, L.T., Todd, W.D., and Fuller, P.M. (2019). Selective
713 activation of serotonergic dorsal raphe neurons facilitates sleep through anxiolysis. *Sleep*.
- 714 Weber, F., and Dan, Y. (2016). Circuit-based interrogation of sleep control. *Nature* 538, 51-59.
- 715 Weissbourd, B., Ren, J., DeLoach, K.E., Guenther, C.J., Miyamichi, K., and Luo, L. (2014).
716 Presynaptic partners of dorsal raphe serotonergic and GABAergic neurons. *Neuron* 83, 645-
717 662.

- 718 Westerfield, M. (1993). The zebrafish book : a guide for the laboratory use of zebrafish
719 (Brachydanio rerio) (Eugene, OR: M. Westerfield).
- 720 Yelin-Bekerman, L., Elbaz, I., Diber, A., Dahary, D., Gibbs-Bar, L., Alon, S., Lerer-Goldshtein,
721 T., and Appelbaum, L. (2015). Hypocretin neuron-specific transcriptome profiling identifies the
722 sleep modulator Kcnh4a. *Elife* 4.
- 723 Yuan, Q., Joiner, W.J., and Sehgal, A. (2006). A sleep-promoting role for the *Drosophila*
724 serotonin receptor 1A. *Curr Biol* 16, 1051-1062.
- 725

Figure 1. Hypothalamic NPVF neurons project to the serotonergic IRa




Figure 1. Hypothalamic NPVF neurons project to the serotonergic IRa. (A,E) Schematic 6-dpf zebrafish brain showing location of hypothalamic (Hy) NPVF neurons (green), and the serotonergic SRa (red) and IRa (magenta). a, anterior; p, posterior; d, dorsal. (B-D) Maximum intensity projection of a brain from a 6-dpf *Tg(npvf:eGFP)* animal (78 μm thick). *npvf*-expressing neurons in the hypothalamus project to the serotonergic raphe nuclei (RN) in the hindbrain (bracket). 5-HT immunohistochemistry labels the RN (bracket), as well as serotonergic populations in the ventral hypothalamus (asterisks) and pretectum. The bracketed region in (B-D) is shown at higher magnification in (I-K) as a maximum intensity projection (50.5 μm thick), with a sagittal view shown in (E-H). Single optical sections are shown in **Figure S1**. Scale: 50 μm (B-D), 20 μm (F-H) and 10 μm (I-K).

Figure 1 – figure supplement 1. Projections of hypothalamic NPVF neurons to the serotonergic IRa shown in single optical sections.




Figure 1 – figure supplement 1. Projections of hypothalamic NPVF neurons to the serotonergic IRa shown in single optical sections. Related to Figure 1. (A,B) Serial optical sections (0.5 μ m thick) in the hindbrain of a 6-dpf *Tg(npvf:eGFP)* animal labeled with a 5-HT-specific antibody (magenta), which were used to generate the image shown in **Figure 1K**. Fibers from *npvf*-expressing neurons (green) do not innervate SRa soma (**A**) but do innervate IRa soma (**B**). (**C**) A 4 μ m thick optical section of a brain from a 6-dpf *Tg(npvf:KalTA4); Tg(uas:nfsb-mCherry); Tg(tph2:eNTR-mYFP)* animal. White bracket indicates the IRa and is magnified in panels (**D,E**), which show 0.6 μ m thick serial optical sections. Fibers from *npvf*-expressing neurons (magenta) do not innervate SRa neurons (green, **D**) but do innervate IRa neurons and their fibers (green, **E**). Hyp, hypothalamus, IRa, inferior raphe; D, dorsal; V, ventral. Scale: 50 μ m (**C**), 10 μ m (**B,E**).

Figure 2. Optogenetic stimulation of NPVF neurons activates serotonergic IRa neurons




Figure 2. Optogenetic stimulation of NPVF neurons activates serotonergic IRa neurons. (A-F) 6-dpf *Tg(npvf:ReaChR-mCitrine); Tg(tph2:GCaMP6s-tdTomato)* and *Tg(npvf:eGFP); Tg(tph2:GCaMP6s-tdTomato)* animals are analyzed for GCaMP6s fluorescence levels in IRa neurons before and after optogenetic stimulation of NPVF neurons. (A) Example of a 6-dpf *Tg(npvf:ReaChR-mCitrine); Tg(tph2:GCaMP6s-tdTomato)* animal showing GCaMP6s and tdTomato fluorescence in IRa neurons. White box indicates the region of the IRa analyzed in subsequent panels. Green and magenta signals in the eyes are due to autofluorescence. (B) Baseline GCaMP6s fluorescence in the IRa was first recorded using two-photon 920 nm light at 8 mW laser power for 38 s (30 frames). NPVF neurons were then optogenetically stimulated using 920 nm light at 38 mW at 2.7 Hz for 3.7 s. GCaMP6s fluorescence in the IRa was then immediately imaged again using 8 mW laser power for 44 s (35 frames). (C) Average GCaMP6s fluorescence in IRa neurons for 10 frames before (Pre) and after (Post) optogenetic stimulation of NPVF neurons. (D,E) Mean \pm SEM GCaMP6s fluorescence of IRa neurons plotted as a function of time, showing pre-stimulation and post-stimulation evoked responses for *Tg(tph2:GCaMP6s-tdTomato)* animals that also contain a *Tg(npvf:eGFP)* (D,F) or *Tg(npvf:ReaChR-mCitrine)* (E,F) transgene. Dashed grey line indicates 0% $\Delta F/F$. n=number of neurons quantified from 4 animals of each genotype. (F) Box plots quantify GCaMP6s $\Delta F/F$ values one frame after stimulation. *** $p < 0.0005$, Mann-Whitney test. Scale: 100 μ m (A), 10 μ m (C).

Figure 2 - figure supplement 1. Validation of two-photon-induced optogenetic stimulation of NPVF neurons.




Figure 2 – figure supplement 1. Validation of two-photon-induced optogenetic stimulation of NPVF neurons. Related to Figure 2. 6-dpf *Tg(npvf:ReaChR)*; *Tg(npvf:GCaMP6s-tdTomato)* animals are analyzed for GCaMP6s fluorescence levels in NPVF neurons before and after optogenetic stimulation of NPVF neurons. (A) Example of a 6-dpf *Tg(npvf:ReaChR)*; *Tg(npvf:GCaMP6s-tdTomato)* animal showing GCaMP6s and tdTomato fluorescence in NPVF neurons. Green and magenta signals in the eyes are due to autofluorescence. White box indicates the region of the hypothalamus that was stimulated and analyzed in subsequent panels. (B) Baseline GCaMP6s fluorescence in NPVF neurons was first recorded using two-photon 920 nm light at 8 mW laser power for 38 s (30 frames). NPVF neurons were then optogenetically stimulated using 920 nm light at 38 mW at 2.7 Hz for 3.7 s. GCaMP6s fluorescence in the IRa was then immediately imaged again using 8 mW laser power for 38 s (30 frames). (C) GCaMP6s fluorescence in NPVF neurons recorded one frame before (Pre) and after (Post) optogenetic stimulation of NPVF neurons. (D,E) Structural images showing the location of each NPVF neuron that were obtained by averaging 10 frames in the green (D) or red (E) channel. (F) Regions of interest (ROI) to quantify GCaMP6s fluorescence in individual NPVF neurons were defined based on nuclear tdTomato fluorescence. (G,H) GCaMP6s and mCitrine $\Delta F/F$ values for individual NPVF neurons (G, 9 neurons, 1 animal) and mean \pm SEM GCaMP6s and mCitrine $\Delta F/F$ values (H, 86 neurons, 5 animals) are plotted as function of time, showing pre-stimulation and post-stimulation evoked responses. (I) Box plots quantify GCaMP6s and mCitrine $\Delta F/F$ values one frame after stimulation for *Tg(npvf:GCaMP6s-tdTomato)* animals that also contain a *Tg(npvf:ReaChR)* (blue) or *Tg(npvf:eGFP)* (black) transgene. n=number of neurons. *** $p < 0.0005$, Mann-Whitney test. Scale: 100 μ m (A), 10 μ m (C-F).

Figure 3. Loss of *npvf* does not enhance the *tph2* mutant sleep phenotype




Figure 3. Loss of *npvf* does not enhance the *tph2* mutant sleep phenotype. (A-D) Average sleep for *npvf* ^{+/-}; *tph2* ^{+/-} (black), *npvf* ^{-/-}; *tph2* ^{+/-} (dark blue), *npvf* ^{+/-}; *tph2* ^{-/-} (gray), and *npvf* ^{-/-}; *tph2* ^{-/-} (light blue) siblings. The graph on the left shows data for all four genotypes. The three other graphs show the same data as separate pair-wise comparisons. (E) Box plots quantify sleep during the day (left) and night (right). White boxes indicate day. Black boxes and gray shading indicate night. n=number of animals. ns p>0.05, *p<0.05, **p<0.01, ***p<0.005, Two-way ANOVA with Holm-Sidak's multiple comparisons test for each indicated pair-wise comparison. The comparison in red indicates no significant difference between *npvf* ^{+/-}; *tph2* ^{-/-} and *npvf* ^{-/-}; *tph2* ^{-/-} siblings.

Figure 4. Chemogenetic ablation of the RN abolishes NPVF neuron-induced sleep




Figure 4. Chemogenetic ablation of the RN abolishes NPVF neuron-induced sleep. (A) Schematic of experiment. Treatment of animals with the small molecule MTZ results in ablation of serotonergic RN neurons in *Tg(tph2:eNTR-mYFP)* animals but not in their non-transgenic siblings. Behavior is then monitored before and during blue light exposure that stimulates *npvf*-expressing neurons in *Tg(npvf:ReaChR)* animals but not in their non-transgenic siblings. (B) 5-dpf *Tg(tph2:eNTR-mYFP)* zebrafish brain showing serotonergic RN neurons and some of their projections (green) and labeled with a 5-HT specific antibody (magenta). The bracketed region is magnified in (C,D) to show co-labeling of RN neurons with mYFP and 5-HT immunoreactivity. Treatment of *Tg(tph2:eNTR-mYFP)* animals with MTZ results in the loss of both 5-HT immunoreactivity (E) and YFP (F) in the RN, but treatment with DMSO vehicle control does not (C,D). MTZ treatment in *Tg(tph2:eNTR-mYFP)* negative siblings does not result in loss of RN neurons. Images are single 4 μ m (B) and 0.6 μ m (C-H) thick optical sections. Scale: 50 μ m (B), 10 μ m (C-H). (I,J) Normalized locomotor activity (top) and sleep (bottom) of 5-dpf *Tg(npvf:ReaChR)* (dark blue and light blue) and non-transgenic sibling controls (black and gray) zebrafish before (Baseline) and during blue light exposure (Stimulation) in *Tg(tph2:eNTR)* negative animals (I) and in *Tg(tph2:eNTR)* positive siblings (J). Box plots quantify locomotor activity and sleep during optogenetic stimulation normalized to baseline of the same genotype. n=number of animals. ns $p > 0.05$, * $p < 0.05$, *** $p < 0.005$, Mann-Whitney test.

Figure 4 – figure supplement 1. Sleep induced by optogenetic stimulation of *npvf*-expressing neurons is abolished in *npvf* and *tph2* mutant animals.




Figure 4 – figure supplement 1. Sleep induced by optogenetic stimulation of *npvf*-expressing neurons is abolished in *npvf* and *tph2* mutant animals. Related to Figure 4. (A,B) 5-dpf *Tg(npvf:ReaChR-mCitrine)* animals and their non-transgenic siblings were analyzed for changes in locomotor activity and sleep in a 96-well plate optogenetic assay. NPVF neurons in the hypothalamus are labeled with the *npvf:ReaChR-mCitrine* transgene. Green fluorescence in the eyes is due to autofluorescence. **(C,D)** Normalized locomotor activity (top) and sleep (bottom) of *Tg(npvf:ReaChR)* (dark blue and light blue) and non-transgenic sibling control (black and gray) animals before (Baseline) and during exposure to blue light (Stimulation) in *npvf* +/- **(C)** and *npvf* -/- **(D)** animals. **(E,F)** Same as **(C,D)** but with *tph2* mutant rather than *npvf* mutant. Because the animals see the blue light, they exhibit a brief startle at light onset that is excluded from analysis, followed by a gradual increase in activity that plateaus after ~15 minutes. Box plots quantify locomotor activity and sleep for each animal during optogenetic stimulation normalized to the baseline of all animals the same genotype. Stimulation of *npvf*-expressing neurons decreases locomotor activity and increases sleep compared to non-transgenic sibling controls in *npvf* +/- animals **(C)** but not in *npvf* -/- siblings **(D)**, and in *tph2* +/- animals **(E)** but not in *tph2* -/- siblings **(F)**. n=number of animals. ns p>0.05, *p<0.05, ***p<0.005, Mann-Whitney test.

Figure 4 - figure supplement 2. Sleep induced by chemogenetic stimulation of *npvf*-expressing neurons is abolished in *tph2* mutant animals.

Tg(npvf:KalTA4); tph2 +/- (n=67) *Tg(npvf:KalTA4); Tg(UAS:TrpV1); tph2 +/-* (n=112)
Tg(npvf:KalTA4); tph2 -/- (n=52) *Tg(npvf:KalTA4); Tg(UAS:TrpV1); tph2 -/-* (n=107)




Figure 4 – figure supplement 2. Sleep induced by chemogenetic stimulation of *npvf*-expressing neurons is abolished in *tph2* mutant animals. Related to Figure 4. (A) Average sleep for 5-dpf *Tg(npvf:KalTA4); tph2 +/-* (black), *Tg(npvf:KalTA4);tph2 -/-* (gray), *Tg(npvf:KalTA4);Tg(UAS:TRPV1-TagRFP-T);tph2 +/-* (dark blue), and *Tg(npvf:KalTA4);Tg(UAS:TRPV1-TagRFP-T);tph2 -/-* (light blue) siblings treated with 2 μ M capsaicin. Box plots quantify sleep during the day (E) and night (F). White boxes indicate day. Black boxes and gray shading indicate night. n=number of animals. ns $p > 0.05$, * $p < 0.05$, *** $p < 0.005$, Two-way ANOVA with Holm-Sidak test.